This post is for paying subscribers only
Already have an account? Sign in.
MannKind Acquires scPharmaceuticals for up to $360M, Expands into Cardiometabolic Medicine
MannKind Corporation acquires scPharmaceuticals, significantly expanding its presence in cardiometabolic medicine with FUROSCIX, an FDA-approved treatment for heart and kidney disease. This strategic move aims to diversify revenue and accelerate growth.